‘Ambitious Platform’ Among EU Proposals For Increasing mHealth Data Use In Regulatory Decision-Making

mHealth data generated by smartphones and wearables show potential for enhancing the clinical evidence used in regulatory decision-making, but there are “notable challenges” that may hinder the use of such data, EU regulators say.

Data Synchronization Of Health Between Smartwatch And Smartphone
The role of digital, specifically mobile devices, in drug development and regulation is expected to grow (Shutterstock)

EU drug regulators have proposed measures to increase the use of mobile health (mHealth) data from tools such as smartphones in their regulatory decision-making for drugs, including the creation of a large health database where patients across Europe can choose to share their data directly on a common platform.

Key Takeaways
  • A newly published EU report reviews relevant literature related to the use of mHealth data in the context of medicine regulation and aims to discuss their utility for regulatory uses.

The role of digital, specifically mobile devices, in drug development and regulation is expected to grow, according to the joint...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pink Sheet

More from Geography

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By 

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.